Neonatology: First Exposure to Antibiotics from the Ethical Perspective of Parents, Physicians, and Regulators

Area of Science:

• Neonatal Medicine
• Bioethics
• Public Health

Background:

• Premature infants exhibit underdeveloped immune systems, increasing susceptibility to infections in the Neonatal Intensive Care Unit (NICU).
• Antibiotic therapy is a critical intervention for neonates, yet concerns exist regarding medication exposure and long-term developmental impacts.
• Parental distress is significant, with trust in the medical team and clear communication being vital for hope during extended intensive care.

Purpose of the Study:

• To examine the ethical landscape of neonatal intensive care, focusing on the perspectives of parents, healthcare providers, and regulatory bodies.
• To assess the degree of meaningful cooperation between stakeholders in NICU decision-making.
• To identify potential conflicts between institutional priorities and clinical practice in managing premature infants.

Main Methods:

• Ethical analysis of stakeholder perspectives in Neonatal Intensive Care Units.
• Review of clinical realities, including infection risks and pharmaceutical exposure in preterm infants.
• Examination of decision-making dynamics and regulatory oversight within the NICU setting.

Main Results:

• Decision-making authority in the NICU predominantly rests with the medical team.
• Parents often have limited influence on treatment choices for their premature infants.
• Regulatory oversight in neonatal care is typically indirect, highlighting a concentration of power.

Conclusions:

• The concentration of decision-making power in the NICU raises ethical questions about stakeholder cooperation.
• Institutional and professional priorities may influence clinical practice, potentially overshadowing parental concerns.
• Effective communication and trust are essential for navigating the complexities of neonatal intensive care and supporting families.